Middle East Pharmaceutical Industries Co. (4016) is listed on Tadawul of the Saudi Exchange (Tadawul) under sector Pharma, Biotech & Life Science. Financial data sourced from CMA-mandated XBRL filings via Sahm Screener (sahmscreener.com).

For fiscal year 2025, Middle East Pharmaceutical Industries Co. reported revenue of SAR 460M, net profit of SAR 97M, and earnings per share of SAR 4.85. Total assets stood at SAR 600M with total equity of SAR 4.16B and total liabilities of SAR 183M.

Operating cash flow for 2025 was SAR 89M, representing a cash conversion ratio of 0.91 relative to net profit. Free cash flow was SAR 54M.

Earnings quality analysis by Sahm Screener: Of every SAR 1.00 in reported net profit for 2025, SAR 0.91 arrived as operating cash. This indicates High quality earnings based on the cash conversion ratio of 0.91.

Key financial ratios for 2025: Return on Equity 2.3%, Return on Assets 16.2%, Net Margin 21.1%, Debt to Equity 0.04.